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What is the best treatment
for gastroesophageal reflux
and vomiting in infants?
■ Evidence-Based Answer 
The literature on pediatric reflux can be divided
into studies addressing clinically apparent reflux
(vomiting or regurgitation) and reflux as measured
by pH probe or other methods (TABLES 1 AND 2).
Sodium alginate reduces vomiting and improves
parents’ assessment of symptoms (strength of 
recommendation [SOR]: B, small randomized 
controlled trial [RCT]). Formula thickened with
rice cereal decreases the number of postprandial
emesis episodes in infants with gastroesophageal
reflux disease (GERD) (SOR: B, small RCT). 
There are conflicting data on the effect of
carob bean gum as a formula thickener and its
effect on regurgitation frequency (SOR: B, small
RCTs). Metoclopramide does not affect vomiting
or regurgitation, but is associated with greater
weight gain in infants over 3 months with reflux
(SOR: B, low-quality RCTs). 
Carob bean gum used as a formula thickener
decreases reflux as measured by intraluminal
impedance but not as measured by pH probe
(SOR: B, RCT). Omeprazole and metoclopramide
each improve the reflux index as measured by
esophageal pH probe (SOR: B, RCT). 
Evidence is conflicting for other commonly
used conservative measures (such as positional
changes) or other medications for symptomatic
relief of infant GERD. There is very limited evi-
dence or expert opinion regarding breastfed
infants, particularly with regard to preservation of
breastfeeding during therapy.
■ Evidence Summary
Regurgitation (“spitting up”) and gastroe-
sophageal reflux are common in infants. In a cross-
sectional survey of 948 parents of healthy infants
aged 0 to 13 months, regurgitation occurred daily
in half of infants from birth to 3 months old,
peaked to 67% at age 4 months, and was absent in
95% by age 12 months.1 Gastroesophageal disease
(GERD) is characterized by refractory symptoms
or complications (pain, irritability, vomiting, fail-
ure to thrive, dysphagia, respiratory symptoms, or
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esophagitis) and occurs in the minority of infants
with reflux.2 This distinguishes the “happy spitter,”
whose parents may simply require reassurance,
from infants who require treatment. 
Unfortunately, most of the available studies do
not make this distinction in their subjects. Also,
available data primarily regard formula-fed
infants, and are insufficient to make recommenda-
tions for breastfed infants. Esophageal pH probe
monitoring is the gold standard for measuring
reflux in research; however, its correlation with
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symptoms is questionable and it is infrequently
used in clinical practice.3 Therefore, recommenda-
tions are focused primarily on treating only clini-
cally-evident reflux (emesis and regurgitation).
Five small RCTs studied the practice of using
formula thickeners (TABLES 1 AND 2). In 1 study,
formula thickened with rice cereal decreased emesis
episodes.4 Two studies of carob bean gum–thick-
ened formula vs plain formula yielded conflicting
results.5,6 In the study showing improvement with
carob bean gum, the parents were not blinded to the
T A B L E 1
INTERVENTION TRIAL DESCRIPTION EFFECT
Carob bean gum* Unblinded crossover RCT (n=14 infants Improved.
0.4 g/100 cc w/regurgitation). Reflux episodes measured Carob bean gum: 15 regurgitations/342 hrs.
by intraluminal impedance and visual Standard formula: 68 
regurgitation score.5 P<.0003
RCT, thickened vs. standard formula (n=20). No improvement.
Outcome: regurgitation score, parental diary.6 Thickened formula: 2.2≠ 1.92 regurgitation
score. Control formula: 3.3 ≠ 1.16.
P=.14
Crossover RCT (n=24). Formula thickened Improved.
with carob bean gum vs rice cereal. Both groups showed improved 
Outcomes: symptom scores and emesis symptom scores and decreased emesis, 
episodes.7 but carob bean gum was superior to rice 
cereal-thickened formula.
Sodium alginate† Double-blind multicenter RCT of alginate vs Improved. 
225 mg/115 cc placebo added to formula or breast milk Alginate: from 8.5 vomiting/regurgitation 
or (n=88). Intention-to-treat analysis.9 episodes to 3 per 24 h.
450 mg/225 cc Funded by manufacturer. 25% dropout rate. Placebo: from 7 episodes to 5 per 24 h. 
Breastfed infants included, but results not P=.009
reported separately.
Rice cereal RCT of thickened vs unthickened formula Improved.
(see also Carob (n=20). Emesis episodes per 90-min Thickened formula:  1.2 +/- 0.7 emesis 
bean gum, above) postprandial period.4 episodes per 90 minutes postprandial
Placebo:  3.9 +/- 0.9 emesis episodes
P=0.015
Metoclopramide Crossover RCT (n=30). Metoclopramide vs No improvement.
0.1 mg/kg 4 times placebo for 7 days. Mean daily symptom Placebo: Symptom count for 
daily count (included vomiting and Placebo 6.5 ≠ 1.3 per day
regurgitation).10 Metoclopramide 5.6 ≠ 1.2
P=.19
Subgroup analysis infants >3 mo showed
greater weight gain for treated infants.
* Used in the UK (Instant Carobel); not widely available in US
† Available in UK as Gaviscon Infant.
Interventions that affect vomiting or regurgitation
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treatment, which may have led to bias favoring the
treatment.5 An uncontrolled, comparative trial of
carob bean gum vs rice cereal suggested superiority
of carob bean gum as a thickener, although both
treatments yielded improvement.7 Carob bean gum
is available in the UK as a powder (Instant Carobel)
but is not widely available in the US.  
Three trials studied the effects of other conser-
vative therapies such as positional changes and
pacifiers on reflux measured by pH probe; unfortu-
nately, none assessed clinical outcomes such as 
emesis or regurgitation.3 Reflux by pH probe was
worsened in a trial studying the infant seat for posi-
tioning. In the trial studying elevating the head of
the bed to 30° in the prone position, reflux meas-
ured by pH probe was also unchanged; prone posi-
tioning is no longer recommended due to the risk of
Sudden Infant Death Syndrome (SIDS).8 The trial of
pacifier use showed improvement of reflux by pH
probe when used in the seated position, but wors-
ening in the prone position. Since pH probe does
not necessarily reflect clinical symptoms, the utility
of the information from these studies is limited.
Only 1 trial of drugs used to treat infant reflux
T A B L E 2
INTERVENTION DESCRIPTION EFFECT
Carob bean gum* Unblinded crossover RCT (n=14 infants Improved. 
0.4 g/100 cc w/regurgitation). Reflux episodes measured Carob bean gum: 536 episodes
by intraluminal impedance and visual  in 342 hours. Placebo: 647 episodes. P<.02
regurgitation score. Limitations: unblinded;
small sample size; no breastfed infants 
included.5
RCT, thickened vs standard formula. No improvement. Reflux index for 
Reflux meas. by 24-h pH probe.6 thickened formula, 11.1 ± 6.1. Standard 
formula, 13.2 ± 4.7. P=.41
Rice cereal RCT of thickened vs unthickened formula No improvement. Thickened formula group: 
(n=20). Reflux measured by scintigraphy.4 26.8 ± 5.8 episodes per 90 min postprandial 
period. Unthickened formula group: 
27.9 ± 4.0. P=NS.
Infant seat at 60° RCT, positioning in infant seat vs prone. Worsened. Infant seat: 16 ± 2.4 episodes 
Episodes of reflux measured by pH probe.3 in 2 h. Prone position: 10 ± 2.3 episodes. 
P=.002
Head of bed at 30° Crossover RCT (n=90). Prone position vs No improvement. Head-elevated 6.2 ± 0.6 
prone/head of bed elevated to 30°. Number episodes per 2 h. Flat prone 7.8 ± 0.8  
and length of reflux episodes, measured episodes per 2 h. P=NS. 
by pH probe.8 Head-elevated 17.1 ± 2.4 minutes longest 
episode. Flat prone 17.9 ± 2.2 minutes. P=NS.
Pacifier use RCT (n=48). Seated vs prone position, with Prone: Worsened from 7.2 ± 1.1 episodes 
or without pacifier; reflux episodes meas. in 2 h without pacifier to 12.8 ± 2.3 
by pH probe.3 w/pacifier. P=.04.
Omeprazole RCT (n=30 irritable infants with reflux or Irritability unchanged. Improved pH: 
(Infants 5–10 kg: esophagitis). Reflux index (% of time pH <4) Omeprazole: Reflux index –8.9% ± 5.6. 
10 mg/d; meas. by pH probe and “cry/fuss time.”11 Placebo: Reflux Index –1.9% ± 2. P<.001.
infants >10 kg: 
10 mg bid)
Metoclopramide Crossover RCT (n=30). Metoclopramide vs Improved reflux index. Metoclopramide:
(0.1 mg/kg placebo for 7 days. Reflux index measured 10.3% (95% CI, 2.4–22.8). Placebo: 13.4% 
4 times daily) by pH probe. Wide confidence intervals.10 (95% CI, 2.8–30.5). P<.001
Interventions that affect pH probe/measured reflux 
measured clinical symptoms. This large manufac-
turer-sponsored RCT found that sodium alginate9
significantly reduced emesis episodes in treated
infants. Sodium alginate is marketed in the UK as
Gaviscon Infant. While this trial included breastfed
infants, it did not report the numbers of breastfed
infants in the 2 treatment groups or present data
separately for breastfed infants. Small RCTs of
metoclopramide10 and omeprazole11 show signifi-
cant improvement in reflux index measured by pH
probe. However, metoclopramide yielded no
improvement in symptom counts, and the omepra-
zole study resulted in no differences in “cry-fuss
time” between treatment groups.  
■ Recommendations from Others
The North American Society for Pediatric
Gastroenterology and Nutrition recommends
thickening agents or a trial of hypoallergenic for-
mula for vomiting infants.2 They caution against
prone positioning and favor proton pump
inhibitors over H2 blockers for symptomatic relief
and healing of esophagitis. They found insufficient
evidence to recommend surgery over medication.
Vanessa McPherson, MD, Carolinas Medical Center and
University of North Carolina-Chapel Hill, Charlotte, NC
Sarah Towner Wright, MLS, Health Sciences Library,
University of North Carolina at Chapel Hill
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■ Clinical Commentary
Lack of age-appropriate RCTs make 
evidence-based treatment difficult 
Gastroesophageal reflux, defined as the 
passage of gastric contents into the esophagus,
is one of the most common gastroesophageal
problems in infants. GERD is a pathological
process in infants manifested by poor weight
gain, signs of esophagitis, persistent respiratory
symptoms or complications, and changes in
neurologic behavior. Gastroesophageal reflux
generally resolves within the first year of life, as
the lower esophageal sphincter mechanism
matures. Traditionally, these infants have been
managed conservatively with feeding schedule
modifications, thickened feeds, changes in 
positions after feeding, and formula changes.
Depending on the history and clinical presenta-
tion of an infant with GERD, more detailed 
evaluation and treatment may be necessary.  
As per the North American Society for
Pediatric Gastroenterology and Nutrition, if an
upper gastrointestinal series has ruled out
anatomic causes of gastroesophageal reflux,
and nonpharmacologic interventions have
failed, an acid suppressive agent is usually the
first line of therapy. The lack of age-appropriate
case definitions and randomized controlled 
trials, however, make it difficult for those 
practitioners who treat infants to have a 
evidence-based protocol for managing GERD. 
Alfreda L. Bell, MD, 
Kelsey-Seybold Clinic, Houston, Tex
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